Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

Houston-based Empower Pharmacy has repeatedly been admonished by the FDA for failing to follow federal rules that ensure drug ...

Eli Lilly (NYSE:LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk's own treatment, Eli Lilly said of the results presented at the European Congress ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

Shares in British meat producer Cranswick slumped about 9% on Monday after UK supermarkets suspended supplies from one of its ...

Britain's Virgin Media O2 said it was combining its enterprise unit with business-to-business telecoms provider Daisy Group ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

In a way, the requiem of the now-dismantled agency can be told through its people — including some entire families, like the ...

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b ...